January 21, 2006















  • Matisse Filled Old Age With Vibrant Colors
    Current mood: determined




    Estate of Henri Matisse

    “La Gerbe,” one of his late works, using cutouts, on view in Paris through July 17, 2005.



    Hélène Adant/Rapho

    Henri Matisse at work on new projects in 1953, when he was 83.


    May 21, 2005

    With No Time for Twilight, Matisse Filled Old Age With Vibrant Colors




    PARIS, May 18 – Henri Matisse had good reason to feel morose in early 1941. France was under German occupation; his wife, Amélie, had left him; and he was suffering from cancer. Before undergoing a risky operation in Lyon, he wrote an anxious letter to his son, Pierre, insisting, “I love my family, truly, dearly and profoundly.” He left another letter, to be delivered in the event of his death, making peace with Amélie.


    But when the surgery was successful,  Matisse quickly bounced back, declaring that he had won “a second life” and, at 71, led his art in remarkable new directions. He had a beautiful Russian-born assistant, Lydia Delectorskaya, to keep him company. And while ill health later returned to slow him down, he remained optimistic until his death in Nice on Nov. 3, 1954, just a few weeks short of his 85th birthday.


    “I haven’t much to complain about,” he wrote to his old friend  André Rouveyre on Sept. 19 of that year. “When I find something is not going well, I look in some satisfying corner and I find I have no reason to complain.” And he added: “We have good friends – can one ask for more? I am still working a bit and I observe that its quality has not fallen, thanks to good discipline. But one must remain modest.”


    The 13 fruitful years that he unexpectedly gained after his cancer operation are the focus of “Matisse: A Second Life,” an invigorating new exhibition at theMusée de Luxembourg here through July 17. It shows him drawing incessantly, painting sporadically, rediscovering the medium of paper cutouts and preparing what he would consider his masterpiece, the paintings and stained-glass windows of the Chapel of the Rosary in Vence, near Nice.


    It also offers fresh evidence of how aged creators can remain energized by their art. Titian and Monet were also painting in their 80′s, Picasso and Chagall  even into their 90′s. Verdi composed “Falstaff” when he was 80; Richard Strauss wrote his “Four Last Songs” at 84. John Huston was 80 when he directed his last movie, “The Dead.” And many writers keep going: Saul Bellow, who died last month at 89, published his last novel only five years ago.


    Still, this is the first time that Matisse’s late years have been examined in France. The show’s Danish curator, Hanne Finsen, writes in the catalog that she has long been fascinated by how, once great artists reach an advanced age, they often forget commercial considerations and display “extraordinary freedom.” This autumnal flowering is what she explores in “Matisse: A Second Life,” which travels to the Louisiana Museum of Modern Art in Denmark this summer.


    She is helped enormously by Matisse’s own words, presented here through his intense correspondence with Rouveyre, a bohemian artist and novelist whom he first met at the École des Beaux-Arts in Paris in 1892 and who became an intimate friend after 1941. Matisse’s letters to Rouveyre, which number more than 1,200 and were donated to the Royal Library in Denmark, serve as a first-person running commentary on his work, health and state of mind.


    His letters and their envelopes are themselves small works of art: the letters often include drawings and poems, while most envelopes are decorated with flowers, stars and baroque handwriting. There is also humor. The fact that Rouveyre lived for some of the time at a boarding house called “La Joie de Vivre” encouraged Matisse to play word games with the address. On one envelope, he simply wrote: “Monseiur Rouveyre, Somewhere in France.”


    Rouveyre himself is present in the show through several sketched portraits, as well as a Cartier-Bresson photograph of him sitting for Matisse. But Rouveyre also serves as the artist’s sounding board: after Matisse sent him 21 pen-and-ink drawings of trees, an accompanying letter explained the experiment. “I am told that Chinese teachers taught their students that when you want to draw a tree, feel as if you were climbing it when you start at the bottom,” he wrote.


    Matisse’s art evidently helped him keep the war at bay, not least in 1944, when Amélie was arrested, and his daughter, Marguerite, was sent to a concentration camp for Resistance activities. While both survived, Matisse had no word of their whereabouts for months on end. Nonetheless, he found solace in the bright colors that had always distinguished his painting. And along with some still lifes, he painted and sketched sensual nudes and couples.


    In response to remarks that he was too old to be engaged in erotic art, he wrote to Rouveyre, “Why, if my feeling of freshness, of beauty, of youth remains the same as it was 30 years ago in front of flowers, a fine sky or an elegant tree, why should it be different with a young girl?”


    Among his first adventures with paper cutouts was a cheerful book called “Jazz,” which Matisse prepared during the war but which was only published in 1947. The lively multicolor forms, both abstract and figurative, seem to echo the voice of a man stubbornly refusing to be cowed by the times. But he was also enchanted by the technique. “The walls of my bedroom are covered with cutouts,” he wrote to Rouveyre in 1948. “I still don’t know what I’ll do with them.”


    Soon afterward, though, it was by using cutouts that he designed the stained-glass windows for the Chapel of the Rosary, a project he took on as a gesture to a young woman who had nursed him in Lyon in 1941 and later became a Dominican nun. The small modern building on the grounds of the Dominican nuns’ residence in Vence took almost four years to complete. It was, Matisse said, the production of “an entire life of work.”


    Two of the three windows show large yellow and blue leaves against a green background, but the window behind the altar – the study for it is on loan here from the Vatican Museums – is more ambitious: it represents “The Tree of Life,” with flowering cactuses and blue leaves scattered across a green curtain hanging over a yellow window.


    Still more testing for this octogenarian artist were the chapel’s paintings: three large figures, including “Virgin and Child,” as well as 14 Stations of the Cross painted on white ceramic tiles. Studies for these works, which are included in this exhibition, illustrate how Matisse began with detailed drawings and gradually reduced them to a handful of black brush strokes.


    The chapel exhausted Matisse, who by then was unable to stand for long periods and had to attach his paint brush to a long pole. But in his home, sitting on his bed or in a wheelchair, he continued to make gouache cutouts. After Rouveyre teased him for embracing religion, Matisse urged his friend to look at his cutout of a naked woman, “Zulma,” at the May Salon in Paris in 1950: “You will see the awakening of the converted,” was his retort.


    The final cutout in this exhibition, “La Gerbe,” multicolored leaves that resemble a spray of flowers, was completed a few months before his death, but it explodes with life. The artist who almost reinvented color in painting had by now found freedom in the simplicity of decoration. “I have the mastery of it,” he told Rouveyre in a letter. “I am sure of it.”






     



     







    Medical Devices




    January 21, 2006


    Medical Devices Are Hot, Which Is Why Guidant Is




    Think of it as the fight for the Bionic Baby Boomer.


    From head to toe, aging boomers are being kept alive and kicking – or at least walking – by an expanding array of devices that combine the newest medical knowledge with the latest breakthroughs in digital electronics and material sciences.


    Already, the medical device field has become one of the most innovative and profitable segments of the economy. And as wave after wave of baby boomers enter their prime health care spending years, the medical device market is expected to grow by double digits for years to come.


    That trend more than any other may explain the current bidding war for the medical device maker Guidant. Many analysts have questioned the financial sanity of Boston Scientific’s latest offer: $27 billion. Guidant’s original suitor, Johnson & Johnson, whose most recent offer was around $25 billion, has until midnight Tuesday to indicate whether it will make yet another bid for the company.


    In many ways, Guidant is a damaged company. Its market share has plunged, and its potential legal liabilities have mounted, after disclosures of fatal product defects that executives evidently knew about long before notifying doctors. But Guidant’s continuing allure is its prime location in the booming medical device industry.


    The industry’s sweet spot now is the $10 billion market for implanted devices that regulate heartbeats; Guidant has been second only to Medtronic in that field. Forecasts call for that market to expand by 15 percent annually for the next five years, with the fastest growth likely to come from the most expensive and profitable products.


    Guidant is also a player in the $7.6 billion market for balloon devices that can be threaded through arteries to clear blockages in blood vessels, and for the tiny metal cylinders called stents that are inserted to keep those vessels from reclosing. The worldwide market for such devices is expected to top $10 billion by 2010.


    The fight for Guidant, though, is only one sign of the boom in medical devices. Even products that have been on the market for decades, like artificial hips and knees, are undergoing technology-driven makeovers.


    The industry ranges from inexpensive equipment like disposable syringes, crutches and home pregnancy test kits to $1.3 million robotic surgery machines used to remove cancerous prostate glands and equally expensive M.R.I. diagnostic machines that can cost additional hundreds of thousands of dollars to install.


    But right now the financial spotlight is on cardiovascular devices like Guidant’s, which treat breakdowns in the heart and circulatory system associated with aging and progressive diseases like diabetes. Drug-coated stents like Taxus from Boston Scientific are estimated to have profit margins approaching 90 percent. Heart-regulating devices like those made by Guidant, Medtronic and St. Jude Medical can cost $25,000 or more and carry gross margins as high as 70 percent.


    The market enthusiasm for medical devices is a bright contrast to the currently cloudy outlook for many traditional drug companies and biotechnology start-ups, which have hit snags in developing major new products.


    “Devices are an area where technology rapidly fuses with medicine,” said Amit Hazan, an analyst at Suntrust Robinson Humphrey in New York who focuses primarily on device companies with market values below $1 billion. With big companies like Boston Scientific and Johnson & Johnson looking to grow by acquiring new product lines and few major medical device players like Guidant for sale, Wall Street has come to regard many of the smaller fry as prime takeover candidates.


    “The index of small-cap companies I follow was up over 40 percent last year,” Mr. Hazan said.


    As always when markets start looking giddy, there are caution flags. Many doctors say that some of the device industry’s innovations, as with a number of drugs, are being marketed too aggressively. Often, too, regulators approve devices based on relatively short-term evidence of benefits that may not end up justifying their costs.


    And some costs are commonly overlooked. Companies like Guidant, for example, are selling ever more sophisticated heart regulating devices. New features include ones enabling the units to deliver more varied forms of stimulation to more regions of the heart. But doctors say the new features, which can add thousands of dollars to a device’s cost and more rapidly drain the battery, are often never employed. Besides the burden on the checkbook of the patient or – more likely, the insurer – the battery-sapping features may require a patient to have a replacement operation in three or four years instead of six or seven.


    And compared with their ties to the drug industry, doctors are much more involved with device companies in developing new products and making improvements to older ones. The sometimes tangled relationships can speed innovation. But they can also lead to overly aggressive use of new products and procedures on patients who might have benefited as well, or better, from other, less profitable treatments.


    Even if insurers and regulators bring some of the excesses to heel, the device companies will continue to be fueled by the same baby boomer demographics on which traditional drug companies and the newer biotechnology industry are also placing their hopes.


    Wall Street firms like Lazard Capital Markets project that the number of Americans over age 60 will increase by at least 30 percent over the next eight years. On average, they will spend more on health care between the ages of 60 and 70 than they did in all their previous decades combined. And by the time they are 85, they will each be spending over $16,000 annually – more than their average bills for food or shelter, according to Alexander K. Arrow, the device industry analyst at Lazard.


    “Baby boomers are descending upon the health care infrastructure of the United States like locusts upon a cornfield,” Mr. Arrow wrote in an industry overview he published last month.


    As recently as the 1990′s, Wall Street was watching the boomer demographic wave mainly for its impact on big drug companies. They flourished as the number of $1 billion drugs jumped from 4 in 1992 to 55 in 2000. Health care investors with a tolerance for risk flocked to biotechnology companies like Amgen, Genentech and Biogen that were using novel methods to create drugs.


    And many of the drug makers that did own device companies viewed them as a drag on growth. Eli Lilly split off Guidant in 1994, and in 2001 Bristol-Myers Squibb did the same with Zimmer Holdings, now the largest maker of hips and other artificial joints.


    But since 2000, earnings growth has slowed for drug makers as blockbuster drugs of the 1990′s came off patent and successors proved hard to find. In the meantime, leading device companies have proved adept at racking up year after year of double-digit revenue and earnings growth. Unlike drug makers, device company can continually tinker with hit products to produce a steady stream of incremental improvements that can be used to justify price increases.


    And unlike drugs, devices can be designed with electronic components that link them to computers and communications networks, allowing data from patients with implants to be monitored remotely. Guidant’s innovations in such patient monitoring and networking, marketed under the Latitude brand name, are among the enhancements it is counting on to help rebuild market share.


    Stock activity in the last five years attests to the diverging fortunes of drug and device makers. From the beginning of 2000 to the end of 2005, the share price of Pfizer, the largest drug company, declined 10.7 percent, while the stock of Medtronic, the largest independent device company, was rising 63.2 percent.


    During the same period Lilly’s share price declined 4.3 percent (assuming dividends were reinvested) while the stock of Guidant, its device offspring, climbed more than 40 percent. Bristol-Myers’s stock fell more than 53 percent, while Zimmer’s rose more than 135 percent.


    Many of the most successful devices emerged in response to the limitations of drugs. Balloon angioplasty and stents clear blockages in blood vessels where blood-thinning drugs can no longer maintain flow. Pacemakers and defibrillators correct heartbeat abnormalities that are impossible to manage chemically. Spinal fusion devices and, more recently, artificial spinal disks have become treatments of last resort in patients for whom drugs and exercise can no longer control back pain.


    Device makers frequently get clearance to sell new products far more easily than drug makers. That is partly because devices rarely have broad side effects. In addition, most new devices are classified as variations on previously approved products, while each new drug is considered a chemically novel substance requiring a full review of its safety and efficacy.


    Regulators have allowed even devices with relatively low or short-term success rates to enter the market after makers positioned them as therapies of last resort. That happened last year with the Food and Drug Administration’s controversial approval of Cyberonics’ electrical stimulator of the vagus nerve, used to treat depression in cases where drug therapy has failed.


    Few drug makers have a clearer view of these dynamics than Johnson & Johnson, whose vast health care empire includes pharmaceuticals – 44 percent of revenue through the first three quarters of last year – but whose many device divisions already contribute more than a third of its revenue and are collectively bigger than Medtronic, the largest independent device company.


    Now Johnson & Johnson’s working knowledge of the device market is being put to the test, as the company assesses how much value even a damaged Guidant is worth in the Battle for the Bionic Boomer.






    .. 



     


    Wednesday, January 18, 2006







    Paris Hilton












    Paris Nixes Playboy















    Between her X-rated video and various skin-baring red carpet slips (accidental or otherwise), we’re probably as familiar with Paris Hilton‘s anatomy as her internist is. And yet, the talent-challenged Greek billion-heir enthusiast says there’s no chance she’ll doff her duds and embrace her inner airbrushed sexpot in the pages of Playboy, no matter how much moolah Hugh Hefner shoves at her.

    “They’ve asked me a million times,” Paris, 24, tells the Las Vegas Review-Journal. “Hef has been after me since I was 17, and I got offered a lot of money.”

    But, she insists, “I’ll never do it,” and offers this rock-solid reason why not: “Because I’m Paris Hilton.”

    The suddenly straight-laced starlet was in Sin City for Saturday’s opening of a new hotspot, but was without underage arm candy Stavros Niarchos, 19, whose recent club-hopping has reportedly attracted the attention of local liquor authorities.

    The moneybags college student was “studying,” Paris explained, adding that they planned to meet Sunday morning to pick out a pet monkey to add to her ever-growing menagerie.

    The unlucky simian will join a motley collection of creatures that, last time we checked, included a couple Chihuahuas, a kinkajou, a ferret and a goat (let’s hope PETA soon intervenes and convinces Paris that a zoo can be a truly happy place for animals).

    By the by, Hilton’s anti-stripping stance comes on the heels of a New York Times profile of Scott Storch, her rumored ex-beau and the producer behind her long-delayed debut album, who coincidentally previews an appropriate song for the paper.

    On “It’s Like That,” Paris, in what is described as “a breathy, digitally enhanced register,” warbles, “Gonna lose my clothes/You like that, don’t you/Let’s get exposed/You know you want to.”

    When asked to comment on Hilton’s vocal abilities, Storch bobs and weaves, claiming, “If people are given the right circumstances and the right track and the right melody, it’s about the conviction. It’s not necessarily about being a god-given virtuoso.”

    Approximate translation: She wouldn’t sound out of place on the “American Idol” loser reel.

    He also admits he treated Paris to a Bentley, but plays it coy as to whether they mixed “business and pleasure.”

    “It’s always a pleasure working with Paris,” he tells the paper. “We were good friends. Let the world figure that out. I take the high road.”

    The album is due out this summer. Consider yourselves warned.

    Next: Sienna Puts Nanny on Notice

Post a Comment

Leave a Reply

Your email address will not be published. Required fields are marked *